Ensure equal sample loading with loading control antibodies from CST.
Expert-reviewed interactive dopamine signaling pathway providing a current overview of Dopamine in Parkinson's Disease. Learn more here.
Explore the NFkB pathway and its impact on inflammation and immune responses. Click here to learn more about this signaling pathway.
Learn about BCR signaling and how it can lead to changes in cell metabolism, gene expression, and cytoskeletal organization. Click here.
Western Blotting troubleshooting guide for easy to solve high and low background issues.
Discover the PI3K Akt pathway and its crucial role in cell growth and survival. Click here to learn more & gain insights into this important signaling cascade
Discover the autophagy pathway and its crucial role in cellular homeostasis. Learn more and uncover the mechanisms of cellular self-degradation here.
Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for &quoPTM Antibody Company of the Year" and for a third year in a row with the award for "Researchers’ Choice."
Designing or troubleshooting flow cytometry experiments to analyze intracellular signaling? Here’s what you need to know.
CiteAb Names Cell Signaling Technology "Antibody Company of the Year" and "Antibody Company Succeeding in Cancer Biology"
CiteAb Names Cell Signaling Technology, "Antibody Company of the Year" and "Researchers’ Choice"
Cell Signaling Technology (CST) Enters Agreement with Roche for CDx Development
Cell Signaling Technology (CST) Drives Sustainability in the Life Sciences Through My Green Lab Sponsorship
Highly specific and sensitive rabbit mAbs against B7 family targets, B7-H3 & B7-H4, are proven to outperform existing clones by WB.
Cancer cells adapt mechanisms to evade death by hijacking mechanisms of immune checkpoint control and modulation of the innate immune response via STING.
Tissue clearing has paved the way for intact brain imaging with molecular phenotyping. The technology is rapidly evolving and shows great potential.
Aug 2006, CST announced the publication of discovery research based on its patent-pending PhosphoScan® proteomics technology, which identified a mutant JAK3 tyrosine kinase as a novel driver in acute myeloid leukemia (AML).
Feb 2008, CST announced continued PhosphoScan® proteomics research project with Bristol-Myers Squibb for kinase inhibitor profiling.
Oct 2007, CST announced the availability of PhosphoScan® profiling technology and PhosphoSite® knowledge base to academic researchers.
Nov 2008, Renewal of a research agreement with Ortho-Biotech Oncology Research & Development, under which CST will employ its patented PhosphoScan® and PTMScan® technologies in research aimed at biomarker discovery and validation for multiple enzyme target classes and lead small-molecule inhibitors.
Dec 2011, CST wins "Best Performing Antibodies" and "Best Breakthrough Products Cancer Research" Categories in Life Science Industry Awards.
Jan 2008, CST entered into an assay development partnership agreement with TTP LabTech Ltd. (TTPLT.
This webinar describes how highly validated antibodies and mouse models can be used to study neurodegenerative conditions like Alzheimer's Disease.
